On-body Drug Delivery Devices Market to Reach US$ 796.1 Million Valuation by 2034, Growing at 6.8% CAGR: TMR Report
Comunicato Precedente
Comunicato Successivo
An on-body drug delivery device is a patched-on device delivering big molecules (biologics) subcutaneously and has been designed for therapies that periodically need a specific quantity of formulated drug. Typical applications comprise proteins such as monoclonal antibodies (mAbs).
The advantages offered by on-body drug delivery devices include higher level of precision at lower dosing increments, home-use with bolus and/or basal profile, automatic needle insertion and retraction, occlusion detection, resusable/disposable concept supporting sustainability, and use of standard glass cartridges. Research states that targeted drug delivery results in enhanced pharmacokinetics such as improved absorption, distribution, metabolism, and excretion (ADME).
Request a PDF Sample of this Report Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84069
Increasing preference for advanced drug delivery systems has widened the scope for on-body drug delivery devices. Advanced drug delivery technologies have proven to enhance treatment outcomes in various ways, which include enhancement of therapeutic efficacy, increasing patient compliance, reducing toxicity, and facilitating novel medical treatments.
Key Takeaways from the Market Study
Key Market Drivers and Trends
On-body Drug Delivery Devices Market Report Scope:
Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84069
Regional Profile
Competitive Landscape
Key participants in the on-body drug delivery devices market are launching new products to strengthen their position. For instance, in September 2023, Corium, Inc. introduced ADLARITY, a donepezil transdermal system in the U.S. to treat patients contracting mile-to-severe Alzheimer's.
In August 2022, Baxter announced that it had obtained clearance from the U.S. FDA for usage of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software. These infusion pumps deliver small quantities of fluid at low rates in neonatal, pediatric, or anesthesia care settings with utmost precision.
Enable Injections Inc., NOVO Engineering, Elcam Medical, Battelle, and Gerresheimer AG are some of the key players covered in the on-body drug delivery devices market report.
Key Players Profiled
Recent Market Developments
Key Segments Profiled
Product Type
Application
End User
Region
Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=84069<ype=S
More Trending Report by Transparency Market Research:
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]
Follow Us: LinkedIn| Twitter| Blog | YouTube
Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/on-body-drug-delivery-devices-market-to-reach-us-796-1-million-valuation-by-2034--growing-at-6-8-cagr-tmr-report-302213340.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




